在岗研究生导师情况介绍
所系名称营养科学研究所
性别女
专业名称生物化学与分子生物学
技术职务研究员
行政职务研究组长
Mail地址huiwang@sibs.ac.cn
指导博士
生总数7指导硕士
生总数6已毕业学生通讯地址上海市太原路294号
目前博士
生数6目前硕士
生数3目前在校生邮政编码200031
研究方向分子营养药学与毒理学
研究工作营养药学、应用药学、药物遗传学、基因组学及代谢组学的研究；原癌基因的调控与沉默－机制的研究及其在新药研发中的应用；基于RNA/DNA的生物工程－高新技术及其在新药研发中的应用；肿瘤微环境与机体相互作用机制的研究及其在新药研发中的应用；新型癌症早期检测手段的研究与应用；新型肿瘤免疫调节剂的研究与应用；天然产物中肿瘤治疗与预防性药物的研究与应用；肿瘤分子流行病学的研究；胚胎早期发育的分子调控；食品安全快速检测新技术、新方法的研究与开发；食品中有毒有害物质危害作用机制的研究。
获奖情况1)入选中国科学院“百人计划”称号(2007)。
2)获上海市优秀女青年科技工作者成才资助金(2007)。
3)中国营养学会年会优秀论文奖(2006)。
4)获美国临床药理和药物学会理事长奖(AmericanSocietyofClinical
PharmacologyandTherapeutics，ASCPT)，并被邀请作大会发言(2000)。
5)被提名为UAB国际学者奖最终候选人(2000)。
6)国际肿瘤预防学会(InternationalSocietyofPreventiveOncology，ISPO)青年学
者奖获得者，并在该学会举办的瑞士日内瓦年会上获得优秀论文奖(2000)。
7)被录入国际专业人士名人录(2000)。
8)天津市科技成果一等奖(排名第一)(1999)。
指导研究
生情况侯俊梅女2005级博士
郝淼男2007级博士
陈涛男2007级博士
陈培战男2008级博士
段娟女2008级博士
巴乾男2008级博士
李晓光男2007级硕士
李绵女2007级硕士
刘燕玲女2007级硕士
个人简介王慧，博士，研究员，博士生导师。1999年在天津医科大学/美国伯明翰阿拉巴马大学(UAB)获得医学、理学博士学位(中美联合培养)；1999年至2001年在UAB大学做博士后研究；2001年至2002年任UAB大学临床药理学、药理与毒理学讲师；2002年至2005年任助理教授、UAB癌症研究中心副研究员及医学院癌症药理学中心实验室副主任；2005年10月至今任中国科学院上海生科院营养所研究员、研究组长(PI)、食品安全研究中心主任、复旦大学兼职教授。申请人长期从事肿瘤信号转导通路及肿瘤预防治疗、人群基因易感性及早期诊断、环境有毒物质作用机制及其快速检测技术研发，在新药的药理和毒理评价领域具有丰富经验，在疾病预防控制、早期诊断及靶向治疗的基础和应用研究中成绩突出，重视学科交叉渗透及多学科综合研究，是2000年美国临床药理和药物学会理事长奖和2000年国际肿瘤预防学会青年学者奖获得者。至今，在PNAS、CancerRes、JBC、Oncogene、ClinCancerRes、MolCancerTher等国际期刊上发表研究论文72篇（其中SCI收录论文56篇、被引用907次），参编书籍3部；国际学术会议大会邀请报告2次；申请国内外专利5项（美国3项、中国2项）；为国际期刊CancerRes、ClinCancerRes、MolCancerTher等的审稿人，为美国国立卫生院癌症研究所(NCI)提交20多个用于新药开发的保密性总结报告；为美国癌症研究协会（AACR）和中国细胞生物学学会（CSCB）和中国生物化学与分子生物学学会（CSBMB）会员；申请国内外专利5项。2006年入选上海市“浦江人才计划”；2007年入选中国科学院“百人计划”，获教育部留学回国人员科研启动基金，上海市科委“白玉兰计划”资助，并获得上海市优秀女青年科技工作者成才资助金。目前承担科技部重大科学研究计划项目及上海市科委重大攻关项目，同时还与政府、企业合作，承担多项药品、保健品、功能性食品以及食品安全检测开发项目。
近期论文1.HouJ,WangD,ZhangR,andWangH*.ExperimentalTherapyofHepatomawithArtemisininandItsDerivatives:InvitroandInvivoActivity,Chemosensitization,andMechanismsofAction.ClinCancerRes.2008accepted(*通讯作者)
2.ChenP,LiangJ,WangZ,ZhouX,ChenL,LiM,XieD,HuZ,ShenH,andWangH*.AssociationofCommonPALB2PolymorphismswithBreastCancerRisk:aCase-ControlStudy.ClinCancerRes.2008.inpress(*通讯作者)
3.ChenT,LiM,ZhangR,andWangH*.DihydroartemisininInducesApoptosisandSensitizesHumanOvarianCancerCellstoCarboplatinTherapy.JCellMolMed.2008May2.(*通讯作者)
4.陈涛,陈露,王慧*.Survivin在卵巢癌的研究进展.国际妇产科学杂志,2008,inpress.(*通讯作者)
5.WangW,WangH*,RayburnER,ZhaoY,HillDL,ZhangR.20(S)-25-methoxyl-dammarane-3β,12β,20-triol,anovelnaturalproductforprostatecancer:activityinvitroandinvivoandmechanismsofaction.BrJCancer.2008Feb26;98(4):792-802.(*共同第一作者及通讯作者)
6.WangW,RayburnER,HaoM,ZhaoY,HillDL,ZhangR,WangH*.ExperimentalTherapyofProstateCancerwithNovelNaturalProductAnti-cancerGinsenosides.Prostate.2008;Mar6;[Epubaheadofprint].(*通讯作者)
7.SaifMW,SellersS,LiM,WangW,CusimanoL,WangH,ZhangR.AphaseIstudyofbi-weeklyadministrationof24-hgemcitabinefollowedby24-hirinotecaninpatientswithsolidtumors.CancerChemotherPharmacol.2007Nov;60(6):871-82.
8.ChenD,ZhangZ,LiM,WangW,LiY,RayburnER,HillDL,WangH*,ZhangR.RibosomalproteinS7asanovelmodulatorofp53-MDM2interaction:bindingtoMDM2,stabilizationofp53protein,andactivationofp53function.Oncogene.2007Aug2;26(35):5029-37.(*通讯作者)
9.RayburnE,WangW,ZhangR.,WangH*.Experimentaltherapyforcoloncancer:anti-cancereffectsofTLR9agonism,combinationwithothertherapeuticmodalities,anddependenceuponp53.IntlJOncol.2007Jun;30(6):1511-9.(*通讯作者)
10.HeJ,ZhouF,ShaoK,HangJ,WangH,RayburnE,XiaoZ,LeeSW.XueQ,FengX,ShiS,ZhangC,ZhangS.OverexpressionofPin1innon-smallcelllungcancer(NSCLC)anditscorrelationwithlymphnodemetastases.LungCancer.2007Apr;56(1):51-58.
11.WangW,ZhaoY,RayburnE,HillDL,WangH,ZhangR.Invitroanti-canceractivityandstructure-activityrelationshipsofnaturalproductsisolatedfromfruitsofPanaxginseng.CancerChemPharm.2007Apr;59(5):589-601.
12.WangH*,WangY,RayburnER,HillDL,RinehartJJ,ZhangR.Dexamethasoneasachemosensitizerforbreastcancerchemotherapy:Potentiationoftheantitumoractivityofadriamycin,modulationofcytokineexpression,andpharmacokinetics.IntlJOncol.2007Apr;30(4):947-53.(*通讯作者)
13.WangH,LiM,LinW,WangW,ZhangZ,RayburnE,LuJ,ChenD,YueX,ShenF,JiangF,HeJ,WeiW,ZengX.ZhangR.ExtracellularactivityofcAMP-dependentproteinkinase(ECPKA)asabiomarkerforhumancancerdetection:distributioncharacteristicsinanormalpopulationandcancerpatients.CanEpidemBiomarkerPrev.2007Apr;16(4):789-95.
14.LiM,ZhangZ,HillDL,WangH,ZhangR.Curcumin,adietarycomponent,hasanti-cancer,chemosensitizationandradiosensitizationeffectsbydown-regulatingtheMDM2oncogenethroughthePI3kinase/mTOR/ETS2pathway.CancerRes.2007Mar1;67(5):1988-96.
15.ZhaoY,WangW,RayburnE,HillDL,WangH,ZhangR.Isolation,StructuralDetermination,andEvaluationoftheBiologicalActivityof20(S)-25-methoxyl-dammarane-3β,12β,20-triol[20(S)-25-OCH3-PPD],aNovelNaturalProductfromPanaxnotoginseng.MedChem.2007;3:51-60.
16.RayburnE,WangW,ZhangZ,LiM,KandimallaER,AgrawalS,ZhangR,WangH*.Experimentaltherapyofprostatecancerwithanimmunomodulatoryoligonucleotide:effectsontumorgrowth,apoptosis,proliferation,andpotentiationofchemotherapy.Prostate.2006Nov1;66(15):1653-63.(*通讯作者)
17.WangZ,WangH,RhieJK,CoveyJM,LiangP,WangS,WangC,HuY,PrasadG,NanL,HillDL,ZhangR.DeterminationofdesoxyepothiloneBinnudemiceplasmabyliquid-liquidextractionandreversed-phasehigh-performanceliquidchromatography.JPharmBiomedAnal.2006Sep18;42(2):272-6.
18.LaCasseEC,Cherton-HorvatGG,HewittKE,MorrisSJ,KandimallaER,YuD,WangH,WangW,ZhangR,AgrawalS,GillardJW,DurkinJP.PreclinicalcharacterizationofAEG35156/GEM640,asecondgenerationantisenseoligonucleotidetargetingXIAP.ClinCancerRes.2006Sep1;12(17):5231-41.
19.WangH,RayburnE,WangW,KandimallaER,AgrawalS,ZhangR.Immunomodulatoryoligonucleotidesasnoveltherapyforbreastcancer:pharmacokinetics,invitroandinvivoanti-canceractivityandpotentiationofantibodytherapy.MolCancerTherapeutics.2006Aug;5(8):2106-14.
20.ZhangRandWangH.Antisensestrategiesforthedevelopmentofnovelcancertherapeutics.In:A.A.AdjeiandJ.K.Buolamwini,eds.NovelAnticancerAgentsStrategiesforDiscoveryandClinicalTesting.ElsevierScience,NewYork,NY.2006;pp193-206.
21.LiM,WangH*,HillDL,StinsonS,VeleyK,GrossiI,PegginsJ,CoveyJM,ZhangR.Preclinicalpharmacologyofthenovelantitumoragentadaphostin,atyrphostinanalogthatinhibitsbcr/abl.CancerChemotherPharm..2006;57(5):607-614.(*通讯作者)
22.RayburnER,WangH,ZhangR.Antisense-basedcancertherapeutics:arewethereyet?ExpertOpiniononEmergingDrugs.2006;11(2):337-52.
23.WangH,RayburnE,WangW,KandimallaER,AgrawalS,ZhangR.Chemotherapyandchemosensitizationofnon-smallcelllungcancerwithanovelimmunomodulatoryoligonucleotidetargetingTLR9.MolCancerTher.2006;5(6):1585-92.
24.ZhangZ,WangH,LiM,AgrawalS,ZhangR.StabilizationofE2F1proteinbyMDM2throughtheE2F1ubiquitinationpathway.Oncogene.2005Nov3;24(48):7238-47.
25.ZhangZ,WangH,LiM,RayburnE,AgrawalS,ZhangR.NovelMDM2p53-independentfunctionsidentifiedthroughRNAsilencingtechnologies.AnnNYAcadSci.2005Nov;1058:205-14.
26.LiM,ZhangZ,HillD,ChenX,WangH,ZhangR.Genistein,adietaryisoflavone,down-regulatestheMDM2oncogeneatbothtranscriptionalandposttranslationallevels.CancerRes.2005Sep15;65(18):8200-8.
27.ZhangZ,LiM,RayburnE,HillDL,ZhangR,WangH*.OncogenesasnoveltargetsforcancerTherapy(partI):Growthfactorsandproteintyrosinekinases.AmJPharmacogenomics.2005;5(3):173-90.(*通讯作者)
28.ZhangZ,LiM,RayburnE,HillDL,ZhangR,WangH*.Oncogenesasnoveltargetsforcancertherapy(partII):Intermediatesignalingmolecules.AmJPharmacogenomics.2005;5(4):247-57.(*通讯作者)
29.ZhangZ,LiM,RayburnE,HillDL,ZhangR,WangH*.Oncogenesasnoveltargetsforcancertherapy((PartIII):Transcription.AmJPharmacogenomics.2005;5(5):327-38.(*通讯作者)
30.ZhangZ,LiM,RayburnE,HillDL,ZhangR,WangH*.Oncogenesasnoveltargetsforcancertherapy(PartIV):Regulatorsofthecellcycle,DNAdamagerepairandapoptosis.AmJPharmacogenomics.2005;5(6):397-407.(*通讯作者)
31.WangH,RayburnE,ZhangR.Syntheticoligodeoxynucleotidescontainingdeoxycytidyl-deoxyguanosinedinucleotides(CpGODNs)andmodifiedanalogsasnovelanti-cancertherapeutics.CurrPharmDes.2005Aug;11(22):2889-907.
32.WangH*,LiM,RhieJK,HockenberyDM,CoveyJM,ZhangR,HillDL.Preclinicalpharmacologyof2-MethoxyantimycinAcompoundsasnovelantitumoragents.CancerChemotherPharm.2005May10;56(3):291-8.(*通讯作者)
33.WangH*,WangZ,WangS,LiM,NanL,RhieJK,CoveyJM,ZhangR,HillDL.PreclinicalpharmacologyofEpothiloneD,anoveltubulin-stabilizingantitumoragent.CancerChemotherPharm.2005May3;56(3):255-60.(*通讯作者)
34.PoseyJA,WangH,HamiltonJ,DelgrossoA,ZhangR,FredaT,ZamboniWC.Phase-Idoseescalationandsequencingstudyofdocetaxelandcontinuousinfusiontopotecaninpatientswithadvancedmalignancies.CancerChemotherPharmacol.2005Apr;56(2):182-8.
35.ZhangR,WangH,AgrawalS.Novelantisenseanti-MDM2mixed-backboneoligonucleotides:Proofofprinciple,invitroandinvivoactivities,andMechanisms.CurrCancerDrugTargets.2005Feb;5(4):43-50.
36.RayburnE,ZhangR,HeJ,WangH*.MDM2andhumanmalignancies:Expression,clinicalpathology,prognosticmarkers,andimplicationsforchemotherapy.CurrCancerDrugTargets2005Feb;5(1):27-42.(*通讯作者)
37.RayburnE,WangH,HeJ,ZhangR.RNAsilencingtechnologiesindrugdiscoveryandtargetvalidation.LettersinDrugDesignandDiscovery.2005Feb;2(1):1-18.
38.RayburnE,WangW,ZhangR,andWangH*.Antisenseapproachindrugdiscoveryanddevelopment.ProgDrugRes.2005;63:227-74.(*通讯作者)
39.LuuHH,ZhangR,HaydonRC,RayburnE,KangQ,SiW,ParkJK,WangH,PengY,JiangW,HeTC.Wnt/beta-cateninsignalingpathwayasanovelcancerdrugtarget.CurrCancerDrugTargets.2004Dec;4(8):653-71.
40.PrasadG,WangH,HillDL,ZhangR.Recentadvancesinexperimentalmoleculartherapeuticsformalignantgliomas.CurrMedChem-Anti-CaAgents2004Jul;4(4):347-61.
41.WangH,LiM,RinehartJJ,ZhangR.Dexamethasoneasachemoprotectantincancerchemotherapy:Hematoprotectiveeffectsandalteredpharmacokineticsandtissuedistributionofcarboplatinandgemcitabine.CancerChemotherPharm2004Jun;53(6):459-67.
42.ZhangZ,WangH,LiM,AgrawalS,ChenX,ZhangR.MDM2isanegativeregulatorofp21(WAF1/CIP1),independentofp53.JBiolChem.2004Apr;279(6):16000-6.
43.WangH,LiM,RinehartJJ,ZhangR.PretreatmentwithDexamethasoneIncreasesAntitumorActivityofCarboplatinandGemcitabineinMiceBearingHumanCancerXenografts:invivoactivity,pharmacokineticsandclinicalimplicationsforcancerchemotherapy.ClinCancerRes.2004Mar;10(5):1633-44.(Featuredarticle)
44.ZhangZ*,WangH*,PrasadG*,LiM,YuD,BonnerJ,AgrawalS,ZhangR.Radiosensitizationbyantisenseanti-MDM2mixed-backboneoligonucleotideininvitroandinvivohumancancermodels.ClinCancerRes.2004Feb15;10(4):1263-73.(*共同第一作者)(Featuredarticle)
45.ZhangR,WangH.Antisensetechnology.In:D.T.CurielandJ.T.Douglas:ContemporaryCancerResearch:CancerGeneTherapy.HumanaPress,Totowa,NJ,2004;pp35-49.
46.WangH,OliverP,ZhangZ,AgrawalS,ZhangR.ChemosensitizationandradiosensitizationofhumancancerbyantisenseAnti-MDM2Oligonucleotides:invitroandinvivoactivitiesandmechanisms.AnnNYAcadSci.2003Dec;1002:217-35.
47.ZhangZ,LiM,WangH,AgrawalS,ZhangR.AntisensetherapytargetingMDM2oncogeneinprostatecancer:Effectsonproliferation,apoptosis,multiplegeneexpression,andchemotherapy.ProcNatlAcadSciUSA.2003Sep30;100(20):11636-41.
48.ZhangRandWangH.AntisenseoligonucleotidestargetingRIasubunitofproteinkinaseA;invitroandinvivoantitumoractivityandpharmacokinetics.MethodsMolMed.2003;75:637-54.
49.ZhangRandWangH.AntisenseoligonucleotideinhibitorsofMDM2oncogeneexpression.MethodsMolMed.2003;85:205-22.
50.KandimallaER,BhagatL,WangD,YuD,ZhuFG,TangJ,WangH,HuangP,ZhangR,AgrawalS.Divergentsyntheticnucleotidemotifrecognitionpattern:designanddevelopmentofpotentimmunomodulatoryoligodeoxyribonucleotideagentswithdistinctcytokineinductionprofiles.NucleicAcidsRes.2003May1;31(9):2393-400.
51.WangH,YuD,AgrawalS,ZhangR.ExperimentaltherapyofhumanprostatecancerbyinhibitingMDM2expressionwithnovelmixed-backboneantisenseoligonucleotides:invitroandinvivoactivitiesandmechanisms.Prostate.2003Feb15;54(3):194-205.
52.BhagatL,ZhuFG,YuD,TangJ,WangH,KandimallaER,ZhangR,AgrawalS.CpGpenta-andhexadeoxyribonucleotidesaspotentimmunomodulatoryagents.BiochemBiophysResComm.2003Jan24;300(4):853-61.
53.ZhangRandWangH.Modulationofgeneexpressionbyantisenseoligonucleotides.In:S.W.KimandR.I.Mahatoeds:PharmaceuticalPerspectivesofNucleicacid-basedTherapeutics.Taylor&Francis:London,UK.2002;pp33-53.
54.YuD,ZhuF,BhagatL,WangH,KandimallaER,ZhangR,AgrawalS.PotentCpGoligonucleotidescontainingphosphodiesterlinkages:invitroandinvivoimmunostimulatoryproperties.BiochemBiophysResComm.2002Sep;297(1):83-90.
55.WangH,HangJ,ShiZ,LiM,YuD,KandimallaER,AgrawalS,ZhangR.AntisenseoligonucleotidetargetedtoRIalphasubunitofcAMP-dependentproteinkinase(GEM231)enhancestherapeuticeffectivenessofcancerchemotherapeuticagentirinotecaninnudemicebearinghumancancerxenografts:invivosynergisticactivity,pharmacokineticsandhosttoxicity.IntJOncol.2002Jul;21(1):73-80.
56.WangH,OliverP,NanL,WangS,WangZ,RhieJK,ZhangR,HillDL.Radiolabeled2'-fluorodeoxyuracil-beta-D-arabinofuranoside(FAU)and2'-fluoro-5-methyldeoxyuracil-beta-
D-arabinofuranoside(FMAU)astumor-imagingagentsinmice.CancerChemotherPharmacol.2002May;49(5):419-24.
57.WangH,WangS,NanL,YuD,AgrawalS,ZhangR.Antisenseanti-MDM2mixed-backboneoligonucleotidesenhancetherapeuticefficacyoftopoisomeraseIinhibitoririnotecaninnudemicebearinghumancancerxenografts:Invivoactivityandmechanisms.IntJOncol2002Apr;20(4):745-52.
58.PrasadG,WangH,AgrawalS,ZhangR.AntisenseoligonucleotidestargetedtoMDM2oncogeneasanovelapproachtothetreatmentofglioblastomamultiforme.AnticancerRes.2002Apr;22:107-16.
59.WangH,NanL,YuD,LindseyJR,AgrawalS,ZhangR.Anti-tumorefficacyofanovelantisenseanti-mdm2mixed-backboneoligonucleotideinhumancoloncancermodels:p53-dependentandp53-independentmechanisms.MolMed.2002Apr;8(4):185-99.
60.WangH,NanL,YuD,AgrawalS,ZhangR.Antisenseanti-MDM2oligonucleotidesasanoveltherapeuticapproachtohumanbreastcancer:invitroandinvivoactivitiesandmechanisms.ClinCancerRes.2001Nov;7(11):3613-24.
61.WangH,PrasadG,BuolamwiniJK,ZhangR.Antisenseanticanceroligonucleotidetherapeutics.CurrCancerDrugTargets.2001Nov;1(3):177-96.
62.ZhangR,WangH.MDM2Oncogeneasanoveltargetforhumancancertherapy.CurrPharmDes.2000Mar;6(4):393-416.
63.ZhangR,WangH.Antisenseoligonucleotidesasanticancertherapeutics.RecentResearchDevelopmentinCancer.2000;2:61-76.
64.WangH,ZengX,OliverP,LeLP,ChenJ,ChenL,ZhouW,AgrawalS,ZhangR.MDM2oncogeneasatargetforcancertherapy:Anantisenseapproach.IntJOncol.1999Oct;15(4):653-60.
65.WangH,CaiQ,ZengX,YuD,AgrawalS,ZhangR.Antitumoractivityandpharmacokineticsofamixed-backboneantisenseoligonucleotidetargetedtotheRIasubunitofproteinkinaseAafteroraladministration.ProcNatlAcadSciUSA.1999Nov23;96(24):13989-94.
